对“CD4+ T细胞介导树突状细胞许可促进多抗原抗白血病免疫反应”的更正。

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-09-17 DOI:10.1002/cam4.71261

引用次数: 0

摘要

Gil-de-Gómez， L., Mattei， J.J, Lee， J.H, Grupp， S.A, Reid， G.S.D., Seif， A.E. (2025)， CD4+ T细胞介导树突状细胞激活促进多抗原抗白血病免疫应答。中华癌症杂志，14:771 - 778。https://doi.org/10.1002/cam4.70508Affiliation 2应该包括“IDIVAL”。它应该是这样写的：“西班牙坎塔布里亚，桑坦德，坎塔布里亚，伊迪瓦尔，坎塔布里亚大学医学院，分子生物系。”我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to “CD4+ T Cells Mediate Dendritic Cell Licensing to Promote Multi-Antigen Anti-Leukemic Immune Response”

Gil-de-Gómez, L., Mattei, J.J., Lee, J.H., Grupp, S.A., Reid, G.S.D. and Seif, A.E. (2025), CD4+ T Cells Mediate Dendritic Cell Licensing to Promote Multi-Antigen Anti-Leukemic Immune Response. Cancer Med, 14: e70508. https://doi.org/10.1002/cam4.70508

Affiliation number 2 should include “IDIVAL.” It should have read: “Department of Molecular Biology, University of Cantabria School of Medicine-IDIVAL, Santander, Cantabria, Spain.”

We apologize for this error.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.